SciTech Oncology Product Pipeline
Selected Product Pipeline
SciTech has developed a novel approach to enhance the bioavailability of hydrophobic (or water insoluble) drugs, including fenretinide. SciTech’s novel drug delivery medium for hydrophobic drugs; namely, the SciTech Drug Delivery Platform (SDP), in combination with fenretinide has led to SciTech’s lead drug candidate ST-001 nanoFenretinide.
SciTech is developing several novel nanoparticle formulations of fenretinide for treating a broad range of cancers from lymphomas and lung cancer to prostate, pancreatic, breast and colon cancers as well as topical formulations for the treatment of various pre-cancerous and cancer conditions of the skin.
SciTech’s lead drug candidate ST-001 nanoFenretinide is targeted for the treatment of T-cell non-Hodgkin's lymphoma (NHL). The company has submitted an Investigational New Drug (IND) Application for ST-001 nanoFenretinide in the treatment of NHL; and, the IND has recently been approved by the U.S. FDA. The FDA has granted Orphan Drug Status for ST-001 nanoFenretinide in the treatment of two types of non-Hodgkin’s lymphoma (NHL): peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
Utilizing the results from its Phase 1 NHL clinical study, SciTech will initiate a clinical trial for the treatment of small cell lung cancer (SCLC) with its nanoparticle formulation of fenretinide (nanoFenretinide).
The fact that nanoparticle formulations of fenretinide can also be incorporated into topical products has led to the development of nanoFenretinide formulations for the treatment of various pre-cancerous and cancer conditions of the skin (ST-002 nanoFenretinide).
In addition to ST-001 nanoFenretinide for the treatment of NHL and the ST-002 nanoFenretinide topical formulation, SciTech is currently targeting nanoFenretinide (fenretinide) formulations for the followinng cancer indications:
Intravenous formulation for the treatment of SCLC.
Intravenous formulation for the treatment of metastatic breast cancer (MBC).
Intravenous formulation for the treatment of neuroblastoma (pediatric cancer).
Intravenous formulation for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).
The significant safety profile of fenretinide is eminently suitable for its use as a standalone drug; or, in combination with; or, in co-administration with existing cancer treatments (immunotherapy, chemotherapy, radiation and surgery).
A major benefit of fenretinide’s minimal side effects is its non-overlapping toxicity with other cancer treatments. In other words, fenretinide plus other treatments equal enhanced therapeutic performance without worsening toxicity. Fenretinide offers an additional layer of treatment in reducing breakout recurrences and metastatic spread after personal immunotherapies and other treatments have done their best.
The combination of fenretinide’s minimal side-effects and the fact that it simultaneously targets multiple cancer mechanisms of action (MOA) gives it a broad therapeutic reach. Fenretinide has also been shown to have both therapeutic and preventive anti-cancer capabilities.
Dramatic results have been observed in some cancer patients treated with personalized therapies; however, only a minority of patients respond to the immunotherapy. Furthermore, the durability of the personalized immunotherapy treatment is still unknown, while fenretinide has both therapeutic and preventive anti-cancer capabilities.
SciTech's nanoparticle drug delivery platform (SDP) technology holds the promise of enhancing the therapeutic performance of other cancer and non-cancer drugs with similar solubility profiles (hydrophobic drugs) as well as the possibility of drug repurposing.